EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances and Prospects in RNA Drug Development

Hidenori Tani iD

International Journal of Molecular Sciences · 15.11.2024 · 25 (22) · 12284

DOI: 10.3390/ijms252212284 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.11.2024. Verfasst von Hidenori Tani. Beteiligte Einrichtung: Department of Health Pharmacy, Yokohama University of Pharmacy, 601 Matano, Totsuka, Yokohama 245-0066, Japan. Hauptthemen laut MEDLINE: Drug Development, MicroRNAs, RNA, Small Interfering, Oligonucleotides, Antisense. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA therapeutics have undergone remarkable evolution since their inception in the late 1970s, revolutionizing medicine by offering new possibilities for treating previously intractable diseases. The field encompasses various modalities, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs), each with unique mechanisms and applications. The foundation was laid in 1978 with the discovery that synthetic oligonucleotides could inhibit viral replication, followed by pivotal developments such as RNA interference’s discovery in 1998. The COVID-19 pandemic marked a crucial turning point, demonstrating the potential of mRNA vaccines and accelerating interest in RNA-based approaches. However, significant challenges remain, including stability issues, delivery to target tissues, potential off-target effects, and immunogenicity concerns. Recent advancements in chemical modifications, delivery systems, and the integration of AI technologies are addressing these challenges. The field has seen notable successes, such as approved treatments for spinal muscular atrophy and hereditary transthyretin-mediated amyloidosis. Looking ahead, RNA therapeutics show promise for personalized medicine approaches, particularly in treating genetic disorders and cancer. The continued evolution of this field, driven by technological innovations and deeper understanding of RNA biology, suggests a transformative impact on future medical treatments. The purpose of this review is to provide a comprehensive overview of the evolution, current state, and prospects of RNA therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentMicroRNAsRNA, Small InterferingOligonucleotides, AntisenseHumansSARS-CoV-2COVID-19COVID-19 Drug TreatmentRNA, MessengerRNA InterferenceAnimals

Stichwörter der Autor:innen

CRISPR-Cas9 guide RNAsRNA therapeuticsantisense oligonucleotidesaptamersmessenger RNAsmicroRNAssmall interfering RNAs

Substanzen

MicroRNAsRNA, Small InterferingOligonucleotides, AntisenseRNA, Messenger

Autor:innen und Institutionen

  • Department of Health Pharmacy, Yokohama University of Pharmacy, 601 Matano, Totsuka, Yokohama 245-0066, Japan.

ORCID-Profile: Hidenori Tani

Zitieren

APA

Tani, H. (2024). Recent Advances and Prospects in RNA Drug Development. International Journal of Molecular Sciences, 25(22), 12284. https://doi.org/10.3390/ijms252212284

Vancouver

Tani H. Recent Advances and Prospects in RNA Drug Development. International Journal of Molecular Sciences. 2024;25(22):12284. doi:10.3390/ijms252212284

BibTeX
@article{Tani2024,
  author = {Tani, Hidenori},
  title = {Recent Advances and Prospects in RNA Drug Development},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {22},
  pages = {12284},
  doi = {10.3390/ijms252212284}
}
Kostenlos starten →